How should we be using biomarkers in trials of disease modification in Parkinson’s disease?

por Vijiaratnam, Nirosen, Foltynie, Thomas
Publicado 2023

Not only loud but also intelligible

por Foltynie, Tom, Grover, Tim
Publicado 2020

Therapies to Slow, Stop, or Reverse Parkinson’s Disease

por Foltynie, Tom, Langston, J. William
Publicado 2018

Parkinson’s disease dementia: a neural networks perspective

por Gratwicke, James, Jahanshahi, Marjan, Foltynie, Thomas
Publicado 2015

Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease: The Effect of Varying Stimulation Parameters

por Dayal, Viswas, Limousin, Patricia, Foltynie, Thomas
Publicado 2017

Critical Aspects of Clinical Trial Design for Novel Cell and Gene Therapies

por Kefalopoulou, Zinovia, Aviles-Olmos, Iciar, Foltynie, Thomas
Publicado 2011

Understanding and Prevention of “Therapy-” Induced Dyskinesias

por Aviles-Olmos, Iciar, Kefalopoulou, Zinovia, Foltynie, Thomas
Publicado 2012

The Use of Deep Brain Stimulation in Tourette Syndrome

por Akbarian-Tefaghi, Ladan, Zrinzo, Ludvic, Foltynie, Thomas
Publicado 2016

How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?

por Mahlknecht, Philipp, Foltynie, Thomas, Limousin, Patricia, Poewe, Werner
Publicado 2022

The frequency and validity of self-reported diagnosis of Parkinson's Disease in the UK elderly: MRC CFAS cohort

por Foltynie, Thomas, Matthews, Fiona E, Ishihara, Lianna, Brayne, Carol
Publicado 2006

Technologies Assessing Limb Bradykinesia in Parkinson’s Disease

por Hasan, Hasan, Athauda, Dilan S., Foltynie, Thomas, Noyce, Alastair J.
Publicado 2017

Standardised Neuropsychological Assessment for the Selection of Patients Undergoing DBS for Parkinson's Disease

por Foley, Jennifer A., Foltynie, Tom, Limousin, Patricia, Cipolotti, Lisa
Publicado 2018

Video-Based Analyses of Parkinson’s Disease Severity: A Brief Review

por Sibley, Krista G., Girges, Christine, Hoque, Ehsan, Foltynie, Thomas
Publicado 2021

Ropinirole, a dopamine agonist with high D(3) affinity, reduces proactive inhibition: A double-blind, placebo-controlled study in healthy adults

por Rawji, Vishal, Rocchi, Lorenzo, Foltynie, Tom, Rothwell, John C., Jahanshahi, Marjan
Publicado 2020

The effects of deep brain stimulation of the pedunculopontine nucleus on cognition in Parkinson's disease and Progressive Supranuclear Palsy()

por Leimbach, Friederike, Gratwicke, James, Foltynie, Tom, Limousin, Patricia, Zrinzo, Ludvic, Jahanshahi, Marjan
Publicado 2019

Dynamic Network Connectivity Reveals Markers of Response to Deep Brain Stimulation in Parkinson’s Disease

por Wu, Chengyuan, Matias, Caio, Foltynie, Thomas, Limousin, Patricia, Zrinzo, Ludvic, Akram, Harith
Publicado 2021

Dopaminergic Modulation of Sensory Attenuation in Parkinson's Disease: Is There an Underlying Modulation of Beta Power?

por Macerollo, Antonella, Limousin, Patricia, Korlipara, Prasad, Foltynie, Tom, Edwards, Mark J., Kilner, James
Publicado 2019

The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease

por Cheong, Julia L.Y., de Pablo-Fernandez, Eduardo, Foltynie, Thomas, Noyce, Alastair J.
Publicado 2020

Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series

por Foltynie, T., Magee, C., James, C., Webster, G. J. M., Lees, A. J., Limousin, P.
Publicado 2013

Apathy and Reduced Speed of Processing Underlie Decline in Verbal Fluency following DBS

por Foley, Jennifer A., Foltynie, Tom, Zrinzo, Ludvic, Hyam, Jonathan A., Limousin, Patricia, Cipolotti, Lisa
Publicado 2017